Mechanisms of action of endocrine treatment in breast cancer

被引：39

作者：

Lonning, PE ^{[1
]}

Lien, EA ^{[1
]}

机构：

[1] HAUKELAND UNIV HOSP, DEPT CLIN BIOCHEM,DIV PHARMACOL, N-5021 BERGEN, NORWAY

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 1995年 / 21卷 / 1-3期

关键词：

D O I：

10.1016/1040-8428(94)00172-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

收藏

页码：158 / 193

页数：36

相关论文

共 542 条

[1] ABE O, 1992, LANCET, V339, P71
[2] ABE O, 1991, AM J CLIN ONCOL-CANC, V14, pS40
[3] ABULHAJJ YJ, 1982, CANCER RES, V42, P3373
[4] ADAM HK, 1980, CANCER TREAT REP, V64, P761
[5] AHMAD B, 1988, BRIT J PHARMACOL, V93, P215
[6] TREATMENT OF METASTATIC BREAST-CANCER PATIENTS WITH DIFFERENT DOSAGES OF MEGESTROL-ACETATE - DOSE RELATIONS, METABOLIC AND ENDOCRINE EFFECTS
ALEXIEVAFIGUSCH, J
BLANKENSTEIN, MA
HOP, WCJ
KLIJN, JGM
LAMBERTS, SWJ
DEJONG, FH
DOCTER, R
ADLERCREUTZ, H
VANGILSE, HA
[J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (01): : 33 - 40
[7] ALLEGRA JC, 1985, SEMIN ONCOL, V12, P3
[8] RANDOMIZED TRIAL OF TAMOXIFEN VERSUS AMINOGLUTETHIMIDE AND VERSUS COMBINED TAMOXIFEN AND AMINOGLUTETHIMIDE IN ADVANCED POSTMENOPAUSAL BREAST-CANCER
ALONSOMUNOZ, MC
OJEDAGONZALEZ, MB
BELTRANFABREGAT, M
DORCARIBUGENT, J
LOPEZLOPEZ, L
BORRASBALADA, J
CARDENALALEMANV, F
GOMEZBATISTE, X
FABREGATMAYOL, J
VILADIUQUEMADA, P
[J]. ONCOLOGY, 1988, 45 (05) : 350 - 353
[9] ANKER G, 1995, INT J CANCER, V60, P365
[10] [Anonymous], 1992, Lancet, V339, P1

← 1 2 3 4 5 6 7 8 9 10 →